The independent source for health policy research, polling, and news.
381 - 400 of 466 Results
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from âbiosimilars.â Itâs a very different story in Europe.
The new-generation gadget is designed to alert and protect wearers from falls and heart problems, expanding Appleâs target audience beyond the usual, tech-savvy, early adopters to those with older tickers.
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
In this episode of KHNâs âWhat the Health?â Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHNâs Jay Hancock about the latest âBill of the Month.â
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Joanne Kenen of Politico and Anna Edney of Bloomberg News discuss the latest on open enrollment for the Affordable Care Act and Medicare; new moves by the Food and Drug Administration to regulate tobacco and nicotine products; and whether House Democrats will pursue a âMedicare-for-allâ bill in the next Congress. Plus, for extra credit, the panelists recommend their favorite health policy books for your holiday reading and gifting pleasure.
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didnât find the same promise for over-the-counter fish oil supplements when tested in healthy people.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
Dieters and gym rats, beware. Some dietary supplements promising weight loss or more muscle may contain active ingredients not listed on the label that fly under the radar of the Food and Drug Administration. The California Department of Public Health analyzed public data maintained by the FDA to suss out trends among tainted products, raising red flags.
In this episode of KHNâs âWhat the Health?â Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administrationâs announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
Just weeks before midterm elections, a move by federal health officials spotlights a contentious issue: the use of human fetal tissue in research. Hereâs what you need to know to understand the debate.
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now thereâs a twist involving an opioid treatment.
The protection is a win for people who get their needed, legitimate drugs from overseas.
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren't proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
An annual government survey of drug use and health shows a dramatic drop in the number of people who tried heroin but an uptick in pot use.
In this episode of KHNâs âWhat the Health?â Sarah Jane Tribble of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Kimberly Leonard of the Washington Examiner and Rebecca Adams of CQ Roll Call talk about the Food and Drug Administrationâs latest actions to address teenagersâ use of e-cigarettes, Arkansasâ Medicaid work requirements and news about the uninsured from the latest federal Census report.
The Golden State, with the rare support of the Trump administration, is seeking to circumvent a court order that would require cancer warnings in every establishment that sells a hot cup of Joe.
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico discuss Senate action on health funding and opioid legislation, the state of the individual insurance market and consternation over expiration dates on EpiPens, the self-injected allergy remedy. Also, could an otter with asthma signal a potential public health crisis?
© 2026 KFF